phase 3

Red arrow decreasing
Biotech

Neuphoria nixes social anxiety program after phase 3 flop

Neuphoria’s stock has plummeted 67% after the announcement, dropping from Monday’s close of $15.40 per share to $5 as of 10 a.m. ET today.
Gabrielle Masson Oct 21, 2025 10:44am
An arrow incrementally going up stairs before pointing straight up Blue background

Praxis plots path to FDA after phase 3 wins in essential tremor

Oct 16, 2025 11:48am
heart money

Cytokinetics’ ph. 3 cardio win sends stock soaring

Sep 2, 2025 2:05pm
Cartoon of businessmen standing around a broken target

Spine BioPharma misses primary endpoint in back pain phase 3

Aug 1, 2025 10:24am
Whale swimming in ocean seen from above

Merck wades deeper into HIV PrEP waters with pair of trials

Jul 14, 2025 1:12pm
Goal disorientation and lack of vision

UPDATED: Taiho’s discontinues ph. 3 trial after DMD miss

Jul 8, 2025 10:17am